‹ Back
Tirzepatide
What it helps
Appetite and food noise, body fat and the waist, blood sugar and insulin, the liver, and the heart and blood vessels.
Sources
Read the original sources
- Semaglutide lowers body weight in rodents via distributed neural pathways (2020 · Abstract; rodent mechanism · checked 2026-10-13)
- A contemporary rationale for GIP receptor agonism in obesity, Samms 2025, Diabetes (Abstract · checked 2026-10-13)
- SURMOUNT-1: tirzepatide and obesity (Jastreboff and colleagues · 2022 · Published abstract · checked 2026-10-08)
- Abdominal fat and metabolic markers on tirzepatide in Japanese people with obesity disease, Waki 2026, Endocrine Practice (SURMOUNT-J) (Abstract · checked 2026-10-13)
- LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. (Coskun · 2018 · Abstract; full methods not assumed · checked 2026-10-13)
- Tirzepatide versus semaglutide once weekly in type 2 diabetes, Frias 2021, NEJM (Abstract · checked 2026-10-13)
- Tirzepatide: unimolecular polypharmacology for obesity, 2025, Endocrinology: News, Opinions, Training (Russia) (Summary · checked 2026-10-13)
- Dual GIP/GLP-1 receptor agonist tirzepatide, the new incretin summit, 2026, Effective Pharmacotherapy (Russia) (Summary · checked 2026-10-13)
- Tirzepatide for weight reduction in Chinese adults with obesity, Zhao 2024, JAMA (SURMOUNT-CN) (Abstract · checked 2026-10-13)